Cystic Fibrosis, nasal polyps, rhinosinusitis, Taaislijmziekte, neuspoliepen, rhinosinusitis
Conditions
Interventions
None listed
Sponsors
H.G.M. Heijerman, MD PhD & M.C. Berkhout, MD
Pulmonary Department
Haga Teaching Hospital, The Hague
Eligibility
Inclusion criteria
Inclusion criteria: 1. Confirmed diagnose of Cystic Fibrosis based on genotyping or a positive sweat test; 2. Age equal to or above 18 years.
Exclusion criteria
Exclusion criteria: 1. Gross immunodeficiency (congenital of acquired); 2. Congenital mucociliary problems other than CF (e.g. Primairy ciliary dyskinesia); 3. ASA syndrome (Samter's triad; nasal polyps, asthma and aspirin sensitivity); 4. Cocaine abuse; 5. Intranasal neoplasia; 6. Systemic vasculitis and granulomatous diseases (e.g. M.Wegener, sarcoidosis, Churg-Strauss syndrome); 7. Allergy or intolerance to xylometazoline and lidocaine; 8. Pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of rhinosinusitis and/or nasal polyps. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Disease specific quality of life (score on Rhinosinusitis Outcome Measure-31); 2. Outcome of ENT examination (on a standardized form); 3. Upper airway cultures (nasal lavage and middle meatal swabs); 4. Sputum cultures; 5. Nasal airway resistance; 6. Computed tomography of sinuses and volume estimation of sinuses. | — |
Contacts
Public ContactMaaike Berkhout
Leyweg 275
Outcome results
None listed